| Market Research A to Z | Company Profiles A to Z | Register | Contact Us |
| +44 (0) 203 086 8600 Call us on |
Halozyme Therapeutics, Inc. - Product Pipeline Review - 2012
Market |
Healthcare and Medical |
Report Type |
Company Profile |
Country |
Global |
Published |
31 August 2012 |
Number of Pages |
67 |
1-3 hours, 24 hour max |
|
Publisher |
Global Markets Direct |
File Format |
This report is built using data and information sourced from our proprietary databases, Halozyme Therapeutics, Inc.'s corporate website, SEC filings, investor presentations and featured press releases, both from Halozyme Therapeutics, Inc. and industry-specific third party sources, put together by This team.
Scope
- Halozyme Therapeutics, Inc. - Brief Halozyme Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Halozyme Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Halozyme Therapeutics, Inc. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Halozyme Therapeutics, Inc.'s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate Halozyme Therapeutics, Inc.'s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Halozyme Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Halozyme Therapeutics, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Halozyme Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Halozyme Therapeutics, Inc. and identify potential opportunities in those areas.
Keywords
Current R&D Portfolio of Halozyme Therapeutics, Inc.; Halozyme Therapeutics, Inc. - Key Therapeutics; Halozyme Therapeutics, Inc. - Pipeline Overview and Promising Molecules; Halozyme Therapeutics, Inc. - News; Halozyme Therapeutics, Inc. - Latest Updates; Halozyme Therapeutics, Inc. - Pipeline; Halozyme Therapeutics, Inc. - Discontinued/Dormant Projects
Visitor Comments
|
All posts are pre-moderated and must obey the house rules. |
|
Competitor Tracking
Do you need to track your competitors and customers on a continuous basis? We have the expertise to provide you with a cost-effective, fully customised competitor tracking portal, which collates data on your competitors on a continuous basis. Contact us for a free consultation and demonstration.
Become an Affiliate
Do you manage an industry specific website or blog? Are you looking to monetise your web traffic further? Are you a B2B website?
Why not offer your visitors industry specific strategic market reports and company profiles? Our Affiliate Program enables you to provide quality content on your website and to earn money from passing on visitors to our website.
Custom Research
Cannot find what you need? We can tailor a report for you. Complete the Custom Research Form and we will provide a quote.
News
Digital pathology market to reach a value of $542 million by 2018
Infectious disease treatments market driven by growth in middle-income to low-income countries
OCT imaging market led by Carl Zeiss and St. Jude Medical
Healthcare decision support market led by McKesson and IBM's Watson
